Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - Lonza collaborates on commercial supply manufacturing for anti-coagulation antidote [Syrian Arab News Agency] - February 15, 2019

Pharmacy News Article

 2/7/19 - Lonza collaborates on commercial supply manufacturing for anti-coagulation antidote [Syrian Arab News Agency]

Portola and Lonza will collaborate on commercial supply the API for the formers anti-coagulation antidote at Lonzas facilities.

Portola Pharmaceuticals and Lonza announced a partnership to start a commercial supply of Portolas recently approved, second generation Andexxa (andexanet alfa, recombinant coagulation factor Xa).

Portolas Andexxa is an antidote for the medications Xarelto (rivaroxaban) and Eliquis (aprizaban), when the reversal of anticoagulation is needed for uncontrolled bleeding.

Portola has just received US Food and Drug Administration (FDA) approval for the second gen process and also expects a positive CHMP opinion at the end of February, paving the way for supplying European markets, a spokesperson for Lonza added.

The generation 1 version of the treatment had previously received a complete response letter (CRL) from the FDA due to the need for additional data to be provided regarding chemistry, manufacturing, and controls.

At the time of the CRL, Portola was working with CMC Biologics to manufacture the product in its reactor, as well as the companys single-use bioreactor for the Changes Being Effect (CBE) supplementary FDA submission.

It was then, in 2016, that Lonza was contracted to undertake a higher yield process for the intended expansion of the drug once approved.

Lonza and Portola also worked closely in the development of the second generation manufacturing process for Andexxa and since its approval by the FDA the two companies will continue to work together through the commercial supply collaboration.

A spokesperson for Lonza told us, We worked with Portola to design a path to market for this second generation Andexxa which includes our large-scale commercial assets in Porrio, Spain and IbexTM Solutions at our Visp, Switzerland facility.

Production will occur at Lonzas 10,000L mammalian facility in Porrio and be supplemented by additional large-scale capacity in IbexTm Dedicate at Lonzas Switzerland facility when it comes online in 2020. The two sites will ensure flexible supply of Andexxa to patients.

In regard to the transition from one site to two, to ensure manufacturing capacity, the spokesperson stated, Having two sites with the appropriate technology and capacity for Portola means they can ramp up or down as needed and ensures they can keep pace with the market needs in this critical first phase of commercialization.

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement